MHNCS 2024 Poster Presentation: Updated dose expansion results of a Phase 1/1b study of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with[...]

Bicara Therapeutics Inc. published this content on March 01, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 02, 2025 at 10:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]